Clinical trial
Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma
NCT00036426 · Favrille, Industry · Unknown status
Key facts
| NCT number | NCT00036426 |
|---|---|
| Title | Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma |
| Official title | Phase II Study of FavId (Tumor-Specific Idiotype-KLH) and Soluble GM-CSF Immunotherapy in Patients With Stable or Progressive Grade 1 and 2 Follicular B-Cell Lymphomas |
| Lead sponsor | Favrille, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Low-Grade |
| Intervention type | Biological |
| Interventions | FavId (Id-KLH) active immunotherapy |
| Enrollment | 22 |
| Start date | Mar 1, 2001 |
| First posted | May 10, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: